Reviewer’s report

Title: Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: A case report

Version: 0 Date: 10 Apr 2017

Reviewer: Enrico Derenzini

Reviewer's report:

This case report from Lai and coworkers describes the activity of anti PD1 therapy with pembrolizumab in a relapsed case of NK T-cell lymphoma with extranodal lesions.

This report describes a new interesting setting in which anti PD1 therapy could be effective. Main limitations of this report are the poor quality of written English and the paucity of details regarding the described case (radiologic findings and PET/CT images before and after pembrolizumab therapy are not provided). Recently Kwong et al published in Blood their report on 7 relapsed NK T-cell lymphoma patients treated with pembrolizumab, which decreases the novelty of the findings of the present report. With these premises, a single case report on anti PD1 therapy in NK T-cell lymphoma should provide much more details on treatment evaluation of perhaps molecular monitoring of the disease during treatment.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript
Quality of written English
Please indicate the quality of language in the manuscript:

Not suitable for publication unless extensively edited

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal